BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22438026)

  • 1. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network.
    Henes M; Henes JC; Neunhoeffer E; Von Wolff M; Schmalzing M; Kötter I; Lawrenz B
    Lupus; 2012 Aug; 21(9):953-8. PubMed ID: 22438026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network.
    Henes JC; Henes M; von Wolff M; Schmalzing M; Kötter I; Lawrenz B
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S53-6. PubMed ID: 22512886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
    Manger K; Wildt L; Kalden JR; Manger B
    Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.
    Harward LE; Mitchell K; Pieper C; Copland S; Criscione-Schreiber LG; Clowse ME
    Lupus; 2013 Jan; 22(1):81-6. PubMed ID: 23263867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
    Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
    Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
    Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
    Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women.
    von Wolff M; Dittrich R; Liebenthron J; Nawroth F; Schüring AN; Bruckner T; Germeyer A
    Reprod Biomed Online; 2015 Nov; 31(5):605-12. PubMed ID: 26380870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian failure and flares of systemic lupus erythematosus.
    Mok CC; Wong RW; Lau CS
    Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue.
    Chehab G; Krüssel J; Fehm T; Fischer-Betz R; Schneider M; Germeyer A; Suerdieck MB; Kreuzer V; Liebenthron J
    Lupus; 2019 Apr; 28(5):675-680. PubMed ID: 30907296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents.
    Elizur SE; Chian RC; Pineau CA; Son WY; Holzer HE; Huang JY; Gidoni Y; Levin D; Demirtas E; Tan SL
    Rheumatology (Oxford); 2008 Oct; 47(10):1506-9. PubMed ID: 18660508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
    Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with Gonadotropin Releasing Hormone Agonists in Systemic Lupus Erythematosus Patients Receiving Cyclophosphamide: A Long-term Follow-up Study.
    Orefice V; Ceccarelli F; Perrone G; Perricone C; Galoppi P; Pacucci VA; Spinelli FR; Alessandri C; Brunelli R; Conti F
    Isr Med Assoc J; 2020 Jun; 22(6):343-347. PubMed ID: 32558438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles.
    Huong DL; Wechsler B; Vauthier-Brouzes D; Duhaut P; Costedoat N; Lefebvre G; Piette JC
    Semin Arthritis Rheum; 2002 Dec; 32(3):174-88. PubMed ID: 12528082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
    Marder W; McCune WJ; Wang L; Wing JJ; Fisseha S; McConnell DS; Christman GM; Somers EC
    Gynecol Endocrinol; 2012 Aug; 28(8):624-7. PubMed ID: 22296584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Female fertility preservation in autoimmune diseases: possibilities and practises in France].
    Carré-Pigeon F; Schubert B
    Gynecol Obstet Fertil; 2007 Sep; 35(9):853-60. PubMed ID: 17707674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.
    Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A
    Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
    Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
    Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.